Agomab to Participate in Upcoming Conferences

Agomab Therapeutics (Nasdaq: AGMB) announced participation in several 2026 scientific and investor conferences.

Rhea-AI Summary

Agomab Therapeutics (Nasdaq: AGMB) announced participation in several 2026 scientific and investor conferences. Events include a poster on AGMB-447 for idiopathic pulmonary fibrosis at the ATS International Conference and multiple fireside chats and investor meetings across New York, London, San Diego, and Boston.

Argus May 14 session

-1.25% close to close Open Argus

Details

News Market Reaction – AGMB

In the May 14 session, AGMB declined 1.25%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a busy calendar of scientific and investor engagements, including an AGMB-...

Analysis

This announcement details a busy calendar of scientific and investor engagements, including an AGMB-447 poster at the ATS International Conference 2026 and multiple fireside chats and one-on-one meetings through July 15, 2026. In the past year Agomab has raised capital via IPO and reported cash expected to fund operations into the first half of 2029, alongside progress for ontunisertib and AGMB-447. Investors may watch upcoming trial initiations, data readouts, and partnering signals alongside feedback from these conferences.

Key Figures

Poster board number: 904 ATS poster time: 8:15 AM ET ATS poster date: May 20, 2026 +5 more

Poster board number

904

ATS International Conference 2026 poster on AGMB-447

ATS poster time

8:15 AM ET

AGMB-447 poster presentation on May 20, 2026

ATS poster date

May 20, 2026

AGMB-447 poster at ATS International Conference 2026

H.C. Wainwright chat

May 19, 2026, 1:30 PM ET

Fireside chat at H.C. Wainwright 4th Annual BioConnect

RBC conference slot

May 20, 2026, 8:00 AM ET

Fireside chat at 2026 RBC Capital Markets Global Healthcare Conference

JPM symposium date

June 10, 2026

JPM European Healthcare Symposium in London, UK

BIO convention dates

June 22–25, 2026

BIO International Convention in San Diego, CA

Leerink meetings date

July 15, 2026

One-on-one investor meetings at Leerink Partners Therapeutics Forum

Historical Context

3 past events · Latest: Apr 23

3 events

1. Apr 23

   Earnings and outlook

   24h Move

   +3.3%

   Full-year 2025 results, cash runway into 1H 2029, and positive pipeline updates.

2. Mar 26

   Patent and pipeline

   24h Move

   -7.7%

   USPTO patent grant for AGMB-447 with protection through at least 2041.

3. Feb 09

   IPO completion

   24h Move

   -0.4%

   Closing of IPO of 12,500,000 ADSs at $16.00, raising $200M gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

TGFβR1/ALK5 inhibitor, idiopathic pulmonary fibrosis, preclinical species

3 terms

TGFβR1/ALK5 inhibitor medical

"AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment..."

A TGFβR1/ALK5 inhibitor is a drug that blocks the TGF‑β receptor type 1 (also called ALK5), shutting down a cell‑signaling pathway that can drive scarring, abnormal tissue growth, or cancer progression. Think of it as turning down a faulty alarm bell that tells cells to change behavior. Investors care because these molecules are the basis for new therapies with large potential markets but also carry clinical and regulatory risk tied to trial results, safety and clear patient selection.

idiopathic pulmonary fibrosis medical

"Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic..."

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

preclinical species medical

"Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and..."

Preclinical species are the animals used in laboratory studies to test a new drug or medical product before it is tried in humans. Like crash‑testing cars with dummies, these studies reveal safety, dosing and basic effects so regulators and developers can judge whether a candidate is worth advancing; positive or negative results in those species strongly affect program risk, timelines and investor expectations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:

• ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
  
  
• H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
  
  
• 2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
  
  
• JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
  
  
• BIO International Convention. Monday, June 22 - Thursday, June 25, 2026 in San Diego, CA.
  
  
• 2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.
  

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu 
Phone: +49 172 861 8540

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Agomab Therapeutics (NASDAQ: AGMB) present AGMB-447 data at ATS International Conference 2026?

Agomab will present a poster on AGMB-447 at ATS International Conference 2026 on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, Florida, highlighting preclinical and healthy subject data in idiopathic pulmonary fibrosis.

What is Agomab Therapeutics' AGMB-447 and what data will be shared in May 2026?

AGMB-447 is described as an inhaled lung-restricted TGFβR1/ALK5 inhibitor intended for idiopathic pulmonary fibrosis. According to Agomab, the ATS 2026 poster will report robust anti-fibrotic activity and target engagement in preclinical species and healthy subjects.

Which investor conferences will Agomab Therapeutics (AGMB) attend in May 2026?

Agomab plans to join the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ for a fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET, and the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026 at 8:00 AM ET in New York.

What are the June 2026 conference plans for Agomab Therapeutics (NASDAQ: AGMB)?

In June 2026, Agomab is scheduled to participate in the JPM European Healthcare Symposium on Wednesday, June 10, 2026 in London, UK, and the BIO International Convention from June 22–25, 2026 in San Diego, California.

Will Agomab Therapeutics (AGMB) hold one-on-one investor meetings in 2026?

Yes. According to Agomab, the company plans one-on-one investor meetings at the 2026 Leerink Partners Therapeutics Forum on Wednesday, July 15, 2026 in Boston, Massachusetts, giving investors direct access to management for questions on its fibro-inflammation pipeline.